HomeCompareCGDNF vs ABBV

CGDNF vs ABBV: Dividend Comparison 2026

CGDNF yields 1428.57% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CGDNF wins by $450506417.79M in total portfolio value
10 years
CGDNF
CGDNF
● Live price
1428.57%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$450506417.90M
Annual income
$395,979,768,203,621.75
Full CGDNF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CGDNF vs ABBV

📍 CGDNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCGDNFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CGDNF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CGDNF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CGDNF
Annual income on $10K today (after 15% tax)
$121,428.57/yr
After 10yr DRIP, annual income (after tax)
$336,582,802,973,078.50/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CGDNF beats the other by $336,582,802,952,022.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CGDNF + ABBV for your $10,000?

CGDNF: 50%ABBV: 50%
100% ABBV50/50100% CGDNF
Portfolio after 10yr
$225253209.00M
Annual income
$197,989,884,114,196.75/yr
Blended yield
87.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CGDNF
No analyst data
Altman Z
0.2
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CGDNF buys
0
ABBV buys
0
No recent congressional trades found for CGDNF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCGDNFABBV
Forward yield1428.57%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$450506417.90M$102.3K
Annual income after 10y$395,979,768,203,621.75$24,771.77
Total dividends collected$446517047.78M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CGDNF vs ABBV ($10,000, DRIP)

YearCGDNF PortfolioCGDNF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$153,557$142,857.14$11,550$430.00+$142.0KCGDNF
2$2,214,468$2,050,162.12$13,472$627.96+$2.20MCGDNF
3$30,000,943$27,631,462.06$15,906$926.08+$29.99MCGDNF
4$381,953,954$349,852,945.12$19,071$1,382.55+$381.93MCGDNF
5$4,571,417,058$4,162,726,327.26$23,302$2,095.81+$4571.39MCGDNF
6$51,453,661,727$46,562,245,474.49$29,150$3,237.93+$51453.63MCGDNF
7$544,851,809,170$489,796,391,122.49$37,536$5,121.41+$544851.77MCGDNF
8$5,430,224,629,042$4,847,233,193,230.08$50,079$8,338.38+$5430224.58MCGDNF
9$50,959,485,695,016$45,149,145,341,941.08$69,753$14,065.80+$50959485.63MCGDNF
10$450,506,417,897,289$395,979,768,203,621.75$102,337$24,771.77+$450506417.79MCGDNF

CGDNF vs ABBV: Complete Analysis 2026

CGDNFStock

Conroy Gold and Natural Resources plc engages in the exploration and development of mineral properties in Ireland and Finland. The company primarily explores for gold, lead, and zinc deposits. It primarily focuses on the Longford-Down Massif region for its exploration activities. The company was formerly known as Conroy Diamonds and Gold Plc and changed its name to Conroy Gold and Natural Resources plc in January 2011. Conroy Gold and Natural Resources plc was founded in 1995 and is headquartered in Dublin, Ireland.

Full CGDNF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CGDNF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CGDNF vs SCHDCGDNF vs JEPICGDNF vs OCGDNF vs KOCGDNF vs MAINCGDNF vs JNJCGDNF vs MRKCGDNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.